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ABSTRACT
Computed tomography (CT) is a powerful diagnostic tool for invasive aspergillosis (IA) after allogeneic stem
cell transplantation (allo-SCT); however, little information is available concerning CT findings of late IA after
allo-SCT. To characterize CT findings of late IA, we retrospectively examined medical records and high-
resolution CT findings of 27 allo-SCT recipients with late IA. Either acute or chronic GVHD was diagnosed
in 24 patients. All 27 patients were given corticosteroids at IA diagnosis. High-resolution CT findings included
halo (n  12), centrilobular nodules (n  12), ill-defined consolidation (n  13), ground-glass attenuation (n
 8), pleural effusion (n  7), pleural-based consolidation (n  4), and cavitation (n  4). CT findings showing
centrilobular nodules and either halo or cavitation were classified into bronchopneumonia type and angioin-
vasive type, respectively. Angioinvasive-type, bronchopneumonia-type, and combination-type IA were diag-
nosed in 11, 8, and 4 patients, respectively. CT findings were nonspecific in the other 4 patients. One
bronchopneumonia-type case and 2 angioinvasive-type IA cases were subsequently diagnosed as combination
type. Although there were no significant differences in patient characteristics between the 2 types of IA,
bronchopneumonia-type IA had a poorer prognosis than angioinvasive IA (P .022). Halo is a useful diagnostic
marker in late IA as well as early IA, and late IA frequently manifests as bronchopneumonia.
© 2005 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Invasive aspergillosis (IA) is a signiﬁcant compli-
ation of allogeneic stem cell transplantation (allo-
CT) [1]. It occurs in 4.5% to 15.1% of allo-SCT
ecipients [2-5]. Risk factors of IA include neutrope-
ia, transplantation without laminar air ﬂow equip-
ent, transplantation from a matched unrelated do-
or, graft-versus-host disease (GVHD), use of
orticosteroids, older age, and underlying diseases
2-5]. The survival of these patients depends on early R
06iagnosis and prompt initiation of therapeutic mea-
ures; however, microbiological or histopathologic di-
gnosis is rarely established because blood cultures are
arely positive for Aspergillus species and because in-
asive procedures are required to obtain pathologic
pecimens. The difﬁculty in making an early diagnosis
f IA is a critical problem.
Several new techniques have been developed for
A diagnosis. A double direct sandwich enzyme-linked
mmunosorbent assay (EIA; Platelia Aspergillus; Bio-
ad, Marnes la Coquette, France) for galactomannan
a
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Bntigen has a 67% to 100% sensitivity and a 81% to
9% speciﬁcity for the diagnosis of IA [6]. High-
esolution chest computed tomographic (CT) scan-
ing is also beneﬁcial for making an early diagnosis of
A [7,8]. The presence of a CT halo sign is highly
ndicative of IA in neutropenic patients [9]. The cri-
eria of the European Organization for Research and
reatment of Cancer (EORTC)/Mycology Study
roup (MSG) using these measures are widely used
nd validated for clinical diagnosis of IA [10].
There have been changes in the clinical presenta-
ions of IA. It shows a 2-peak pattern in the develop-
ent of IA: ﬁrst at the time of neutropenia in the early
tage of transplantation and then several months after
he transplantation. Recent trends show an increase in
ate IA, which has now come to account for the most
ases of IA [11]. Much remains unknown regarding
he clinical presentation of late IA. Most cases of late
A are not associated with neutropenia, and this indi-
ates possible differences from early IA in terms of the
echanism of pathogenesis and clinical conditions.
hest CT is a powerful diagnostic tool for the diag-
osis of IA during neutropenia, but there are few
eports on late IA after allogeneic hematopoietic stem
ell transplantation. To investigate the value of chest
T scans in the diagnosis of late IA, we reviewed chest
T ﬁndings in patients with late IA after allogeneic
ematopoietic stem cell transplantation.
ATIENTS AND METHODS
ata Collection
We reviewed the medical records and chest CT
ndings of 27 patients who developed late IA after
llo-SCT at the National Cancer Center Hospital,
oranomon Hospital, Tokyo Metropolitan Koma-
ome Hospital, the University of Tokyo Hospital,
eio University Hospital, Hamanomachi Hospital,
nd Fukuoka University Hospital between January
999 and November 2002. Data from participating
enters were derived from questionnaires distributed
o each center. Minimum data required for the inclu-
ion of a patient in this study were age, history of IA
efore transplantation, underlying diseases, prepara-
ive regimens, GVHD prophylaxis, date of transplan-
ation, date of last follow-up, disease status at last
ollow-up, onset of IA, treatment of IA, response to IA
reatment, development of acute or chronic GVHD,
ate of acute or chronic GVHD, date of disease pro-
ression or death, and causes of death.
iagnostic Criteria for Late IA
When patients who had achieved primary engraft-
ent developed IA, it was deﬁned as late IA. Even
fter engraftment, patients with neutropenia (500/ t
B&MTL) or recurrence of underlying diseases were ex-
luded from this study.
IA was categorized as proven, probable, or possi-
le IA, according to the established EORTC/MSG
riteria [10]. Brieﬂy, proven IA was diagnosed when
here was histologic evidence of tissue invasion by
mall and uniform dichotomously branching hyphae
eptate at regular intervals and/or culture ﬁndings
ositive for Aspergillus species from autopsy speci-
ens, mostly the lung, and a compatible clinical pre-
entation. Probable IA was deﬁned as clinical ﬁndings
ompatible with IA and the positive ﬁndings in EIA
or galactomannan antigen. CT ﬁndings were not in-
orporated into the diagnostic criteria of IA in this
tudy. Aspergillus antigen positivity was deﬁned as an
ptical density index of galactomannan higher than
.5 in 2 consecutive blood samples by an EIA (Plateria
spergillus EIA; Bio-Rad). Possible IA was not in-
luded in this study.
anagement of Late IA
When patients developed an antibiotic-resistant
ever, we performed chest CT and some blood tests,
ncluding EIA and (1-3)--d-glucan assay, for the
arly diagnosis of IA [12,13]. When the diagnosis of
A was conﬁrmed or suspected, we generally initiated
mphotericin B 1.5 mg/kg/d.
eview of High-Resolution CT Scan
CT was performed on commercially available he-
ical or multidetector scanners. Helical techniques
onsisted of 10.0-mm collimation for individual scans
f the entire lung (120 kilovolts [peak]; 100-150 mA)
nd reconstruction with a standard algorithm. Addi-
ional high-resolution CT images were obtained in all
atients by using 1.0- to 2.0-mm collimation, a 15- to
0-cm ﬁeld of view, 120 to 150 kilovolts (peak) and
50 to 200 mA per rotation, a 1.0-second gantry
otation, and a high-spatial-frequency reconstruction
lgorithm. Hard-copy images were photographed at
indow settings for lung (center, 700 to 650
ounsﬁeld Units [HU]; width, 1500 to 2000 HU)
nd mediastinum (center, 35 to 40 HU; width, 300 to
00 HU).
The CT images were assessed by 2 independent
adiologists who did not know patients’ characteristics
r clinical courses. They assessed the presence of areas
f ground-glass attenuation, consolidation, centri-
obular nodules, ill-deﬁned nodules, air bronchogram,
avitation, halo, and pleural effusion. When there was
discrepancy in CT diagnosis between the 2 radiol-
gists, they discussed the case and made a ﬁnal diag-
osis.
CT ﬁndings were described on the basis of the
ecommendations of the Nomenclature Committee of
he Fleischner Society [14]. Ground-glass attenuation
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5as deﬁned as an area of hazy increased parenchymal
ttenuation without obscuration of the underlying
ascular markings. Consolidation was deﬁned as opac-
ty obscuring the underlying vessels. Centrilobular
odules were deﬁned when small nodular lesions lo-
ated in the center of secondary pulmonary lobules
ere identiﬁed. Ill-deﬁned nodules were deﬁned when
mall nodular lesions were present, regardless of the
econdary pulmonary lobules. Cavitation included a
ircumscribed enlarged air space with a wall of vari-
ble thickness. A halo sign consisted of a pulmonary
ass or nodule surrounded by a zone or a halo of
ttenuation less than that at the center of the mass but
reater than that of air in the surrounding uninvolved
ung.
efinition
CT ﬁndings showing centrilobular nodules and
ither a halo sign or cavitation were classiﬁed into
ronchopneumonia type and angioinvasive type, re-
pectively. When both bronchopneumonia-type and
ngioinvasive-type ﬁndings presented in CT scans,
hey were classiﬁed into combination type.
A halo sign pathologically corresponds to a central
ungal nodule surrounded by a rim of coagulative
ecrosis [15]. Cavitation is due to sloughed necrotic
ung surrounded by a rim of air, indicating an immune
esponse to the infection [15]. Centrilobular nodules
re common signs of bronchiolar diseases, especially
ronchopneumonia. They predominate in the centers
f secondary pulmonary lobules, often in relation to
entrilobular bronchioles or arteries. Pathologic ex-
mination of the centrilobular nodules shows an air-
ay ﬁlled with exudate, which is also present in the
urrounding alveoli.
tatistical Analysis
The primary objective of this study was to de-
cribe chest CT ﬁndings of late IA. The secondary
bjective was to investigate whether chest CT scans
ay be useful for making an early diagnosis of
ate IA.
Overall survival was determined by using the
aplan-Meier method. Final follow-up was con-
ucted in July 2004. The median follow-up of sur-
iving patients was 16 months (range, 13.8-32.4
onths). Surviving patients were censored on the last
ay of follow-up. The characteristics of patient
roups (angioinvasive type versus bronchopneumo-
ia type) were compared by using the Fisher exact
est or Mann-Whitney U test. Differences between
urvival rates were calculated by using Wilcoxon
og-rank analysis. P values .05 were considered
igniﬁcant. c
08ESULTS
linical Characteristics of IA
Late IA was diagnosed in 27 patients. Patient char-
cteristics are shown in Table 1. Clinical features at IA
iagnosis are shown in Table 2. Either acute or
hronic GVHD was diagnosed in 24 patients, and 27
atients were given corticosteroids.
indings of Chest CT
A total of 111 chest CT scans were obtained dur-
ng the follow-up of 27 patients (median, 3; range,
-13). Chest CT ﬁndings at the establishment of IA
iagnosis included halo (n  12; Figure 1a), centri-
obular nodules (n  12; Figure 1b), ill-deﬁned con-
olidation (n  13), ground-glass attenuation (n  8),
leural effusion (n  7), pleural-based consolidation
n  4), cavitation (n  4), pneumothorax (n  1),
mphysema (n  1), and air bronchogram (n  4).
Angioinvasive-type, bronchopneumonia-type, and
able 1. Backgrounds of Patients with Late Invasive Aspergillosis
n  27)
Variable Data
ge, y, median (range) 50 (22–70)
ex (male/female) 20/7
nderlying disease
Acute myeloid leukemia 5
Acute lymphoblastic leukemia 9
Chronic myelogeneous leukemia 4
Myelodysplastic syndrome 3
Malignant lymphoma 5
Germ cell tumor 1
istory of invasive aspergillosis before
transplantation (yes/no) 2/25
isk for transplantation* (low/high) 7/20
tem cells (peripheral blood/bone marrow) 16/11
LA (matched/mismatched) 25/2
onor (related/unrelated) 19/8
reparative regimen (reduced-intensity†/
myeloablative‡)
GVHD prophylaxis 11/16
Cyclosporine alone 9
Cyclosporine and methotrexate 19
Tacrolimus and methotrexate 5
Cyclosporine and prednisolone 1
VHD indicates graft-versus-host disease.
We divided the risk of transplantation into 2 groups. The low-risk
group was as follows: acute myeloid or lymphoid leukemia in
ﬁrst and second remission, chronic myelogeneous leukemia in
chronic phase, and myelodysplastic syndrome/refractory ane-
mia. The other patients were deﬁned as having high-risk disease.
Reduced-intensity preparative regimens comprised ﬂudarabine/
busulfan (n  7), ﬂudarabine/cyclophosphamide (n  3), and
ﬂudarabine/melphalan (n  1). Antithymocyte globulin was
added in 4 patients.
Myeloablative preparative regimens comprised busulfan/cyclo-
phosphamide (n  8), cyclophosphamide/total body irradiation
(n  2), cytarabine/cyclophosphamide/total body irradiation
(n  4), and others (n  2).ombination-type IA were diagnosed in 11, 8, and 4
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Batients, respectively. CT ﬁndings were nonspeciﬁc in
he other 4 patients. One of the 8 bronchopneumonia-
ype and 2 of the 11 angioinvasive-type aspergillosis
ases were subsequently diagnosed as combination
ype on the basis of follow-up CT scans.
omparison between Angioinvasive-Type and
ronchopneumonia-Type IA
Clinical characteristics were compared between
ngioinvasive-type (n  11) and bronchopneumonia-
ype (n 8) aspergillosis (Table 3). Except for survival
fter IA diagnosis, there were no signiﬁcant differ-
nces in the patients’ characteristics between the 2
ypes of IA.
urvival of IA
Twenty patients ﬁnally died, and IA was a primary
ause of death in 9 patients. One-year overall survival
fter IA diagnosis was 28.1% (95% conﬁdence inter-
al, 10.7%-45.5%).
ISCUSSION
This study revealed that CT manifestations vary in
able 2. Clinical Characteristics of Patients with Invasive Aspergillosis
n  27)
Variable Data
iagnosis of IA (proven/probable*) 4/23
nset, day after transplantation, median
(range) 104 (27-973)
cute GVHD (0-I/II-IV) 3/12
hronic GVHD (limited/extensive/none) 0/12/0
se of corticosteroid (yes/no) 27/0
ose of corticosteroid (<0.5/0.5-1.0/>1.0
mg/kg) 13/9/5
umber of neutrophils (/L), median
(range) 2250 (610-20 400)
umber of lymphocytes (/L), median
(range) 450 (20-10 100)
erformance status† (0-1/2-4) 6/21
ntifungal prophylaxis (fluconazole/none) 2/25
reatment‡
Deoxycholate amphotericin B 19
Liposomal amphotericin B 2
Itraconazole 5
None 1
esponse to antifungal therapy§
(responded/no change/progression) 11/11/4
ortality within 30 d of IA diagnosis 7
A indicates invasive aspergillosis.
All patients with probable IA were positive for circulating galac-
tomannan antigens at least twice. Aspergillus species were cul-
tured from bronchoalveolar lavage (n  3) and sputum (n  1).
Performance status was deﬁned according to the Eastern Cooper-
ative Oncology Group criteria.
One patient had not received any anti-Aspergillus treatments be-
cause invasive pulmonary aspergillosis diagnosis was established
after death.
Twenty-six patients were given anti-Aspergillus treatments.ate IA. A halo sign, which is speciﬁc for IA in neu- s
B&MTropenic patients [9], was observed in 12 of 27 patients
ith late IA. These ﬁndings demonstrate that a CT
alo is common in late IA as well as in early IA.
ecause posttransplantation pulmonary complications
ther than IA rarely manifest a halo, it will be a useful
ign in making a diagnosis of late IA.
This study showed that the airways are common
argets of late IA. Two types of IA involving the
irways have been reported: bronchopneumonia and
racheobronchitis [16]. Although tracheobronchitis,
lso known as ulcerative and pseudomembranous tra-
heobronchitis, was not documented in this study,
ronchopneumonia was common. These ﬁndings
ontrast with previous reports on early IA, in which
spergillus bronchopneumonia occurs in approxi-
ately 10% of cases of IA [16]. The present study, as
ell as previous reports [17-20], demonstrated that
spergillus bronchopneumonia results in peribron-
hial areas of consolidation and that its radiologic
anifestations are nonspeciﬁc and indistinguishable
rom those caused by other microorganisms [21,22].
his study furthermore showed that nonneutropenic
llo-SCT recipients occasionally develop airway as-
ergillosis. These ﬁndings were comparable to those
rom the study of Logan et al. [18], in which 5 of the
patients with airway aspergillosis were not neu-
ropenic but were receiving immunosuppressive
gents. We should recognize that late IA can man-
fest as bronchopneumonia. When patients develop
ntibiotic-resistant bronchopneumonia, we should
e alert to the possibility of IA.
This study suggests a few possible pathologic ex-
lanations for late IA. First, a halo sign reﬂects an
arly pathologic change and may be seen during both
arly IA and an early phase of late IA. As IA
rogresses, angioinvasive type might change into
ronchopneumonia type. Because we regularly obtain
T scans to make an early diagnosis of IA, we could
ave seen early changes of IA. Early detection of a
alo sign leads to an early diagnosis and a prompt
nitiation of aggressive antifungal treatments and may
igure 1. CT ﬁndings of late IA. a, CT image of angioinvasive-type
ate IA: a halo sign. b, CT image of bronchopneumonia-type late IA
howing multiple centrilobular nodule opacities.
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5e associated with a better prognosis of angioinvasive-
ype IA than that of bronchopneumonia-type IA. Sec-
nd, it should be noted that angioinvasive-type and
ronchopneumonia-type IA rarely coexisted in a sin-
le patient. One of 8 patients with bronchopneumo-
ia-type and 2 of 12 patients with angioinvasive-type
spergillosis subsequently developed combination-
ype aspergillosis. These observations suggest that
he 2 types of IA may have distinct etiologies.
hether the difference can be attributed to fungal
r patient factors is unclear. The patient character-
stics were not signiﬁcantly different between the
atients with angioinvasive-type IA and those with
ronchopneumonia-type IA, whereas survivals were
igniﬁcantly different between bronchopneumonia-
ype and angioinvasive-type IA.
Immunity against Aspergillus species is mediated
y 2 types of host responses: innate and adaptive [23].
he innate immunity includes pulmonary alveolar
acrophages that ingest and kill the inhaled conidia
nd neutrophils that mediate hyphal damages. Recent
tudies have demonstrated that T-cell responses may
ave an important role in the host defense against IA
n nonneutropenic patients [24]. GVHD and cortico-
teroids impair phagocytic functions of macrophages
nd T-cell responses [25]. The 2 types of late IA might
eﬂect the differences in host immune responses to
spergillus species in allo-SCT recipients. Third, the
irway is the target of GVHD, and the airway mucosal
amage by GVHD might also contribute to the sus-
eptibility to bronchopneumonia. Further studies with
nimal models and clinical experiences are necessary
o investigate the pathogenesis of late IA.
We believe that this study provides important in-
ormation on late IA; however, it has limitations. First,
his was a retrospective study that involved a small
umber of patients. It might have been inﬂuenced by
nrecognized bias, and further large-scale studies are
arranted. Second, only 3 patients had histopatho-
able 3. Comparison between Angioinvasive-Type and Bronchopneumon
Variable
ge before transplantation (y)
ype of preparative regimen (myeloablative/reduced intensity)
osttransplantation variables
Onset (day after transplantation)
Neutrophils (/L)
Lymphocytes (/L)
Cumulative dose of corticosteroid within 7 d of IA diagnosis
(mg/kg)
Acute GVHD (II-IV) and/or chronic GVHD (present/absent)
esponse to antifungal agents (responded/not responded)
-mo survival
ata are median (range) unless otherwise noted.
Statistically signiﬁcant.ogic evidence of IA, and we made an IA diagnosis
10ccording to the EORTC/MSG criteria [10]. We
gree that considerable uncertainty and controversy
xist regarding the best method for establishing an IA
iagnosis; however, the EORTC/MSG criteria are the
resent consensus among researchers on invasive fun-
al infection in immunocompromised patients. Fi-
ally, some CT signs might have been attributable to
r inﬂuenced by other etiologies, such as superim-
osed infection and allogeneic immune reaction, but
ostmortem examination in the 5 patients did not
upport this possibility.
In conclusion, this study demonstrates that halo
nd multiple centrilobular nodules are common CT
igns in late IA. Halo is a useful diagnostic marker in
ate IA as well as early IA, and late IA frequently
anifests as bronchopneumonia.
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